Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1995-11-17
1998-12-01
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4242771, 530328, 530327, 530350, 530395, A61K 3810, A61K 3900, C07K 708, C07K 1482
Patent
active
058434488
ABSTRACT:
The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.
REFERENCES:
patent: 5342024 (1994-08-01), Boon et al.
Salgaller et al. Cancer Immunol. Immunother. 39:105-116, Aug. 1994.
Burgess et al. J. Cell Biol. 111:2129-38, Nov. 1990.
Lazar et al. Mol. Cell Biol. 8(3):1247-52, Mar. 1988.
Chen Yachi
Chen Yao-tseng
Garin-Chesa Pilar
Old Lloyd J.
Rettig Wolfgang J.
Caputa Anthony C.
Ludwig Institute of Cancer Research
LandOfFree
Tumor rejection antigen precursor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor rejection antigen precursor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor rejection antigen precursor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2393515